Xencor's $39.4 Million Quarterly Profit Leans On A $105.0 Million Alexion Settlement Paid Half In Cash

Alexion has paid $52.5 million of the settlement, so receivables jumped to $64.8 million and nine-month operating cash flow was negative $120.6 million.

Share
Xencor's $39.4 Million Quarterly Profit Leans On A $105.0 Million Alexion Settlement Paid Half In Cash

Xencor, a clinical-stage biotech that designs engineered XmAb antibodies for cancer and autoimmune disease, booked $116.5 million of third-quarter revenue, and $77.4 million of it is the leftover slice of a $105.0 million royalty settlement with Alexion. Only half of the settlement has arrived in cash, which is why a $39.4 million quarterly net profit sits beside a nine-month net loss of $111.2 million.

Half the settlement is still owed

Xencor and Alexion settled on July 29 a dispute over U.S. royalties on Ultomiris. Alexion pays $105.0 million in two equal installments of $52.5 million. The first arrived in August, and the second is due within 14 days after the settlement's one-year anniversary.

Xencor booked $27.6 million of the total as second-quarter revenue and the remaining $77.4 million in the third quarter, as royalties for periods after June 30. The prior 10-Q had said the settlement resolved the uncertainty over that revenue. Alexion has no further U.S. Ultomiris royalty obligation once it has paid in full, and its ex-U.S. royalties are unaffected.

The dispute began March 4, when Alexion said it owed no more U.S. royalties. Xencor constrained that revenue to zero and recorded a $6.6 million reduction in the first quarter.

Profit quarter, loss year

Revenue was $116.5 million against $21.0 million a year earlier. Operating income was $22.9 million for the quarter, but the nine-month operating loss was $92.1 million.

Accounts receivable rose to $64.8 million from $29.3 million at year-end; the Alexion piece was $61.0 million, of which $8.5 million will be paid directly to OMERS, the buyer of some Ultomiris royalties. Cash used in operations was $120.6 million for the nine months, and the company said the receivable build tied to the settlement was a main driver.

Research spending climbed to $84.3 million from $54.4 million a year earlier. General and administrative expense fell to $9.4 million, helped by a non-recurring legal-expense recovery that includes a $7.0 million payment from Merus, which settled its patent dispute with Xencor in July.

Cash and marketable debt securities were $555.7 million, down from $610.8 million at year-end. Xencor's runway language now reads into 2029, and it expects to end 2026 with $480 million to $500 million.

Pipeline and royalty obligations

Xencor picked a 400 mcg/kg intravenous dose of XmAb819, its kidney-cancer T-cell engager, for Phase 3. Five of 11 evaluable patients had confirmed partial responses, a 45.5% confirmed response rate. It plans to talk to the FDA in the first half of 2027 about a possible accelerated approval path.

The liability for royalties sold to OMERS fell to $95.1 million from $119.7 million at year-end. The Ultomiris effective interest rate was 17.0%. Xencor is obligated to cover some OMERS royalty shortfalls, and $5.0 million of its cash is restricted for that purpose.

The second $52.5 million installment is due within 14 days after the settlement's one-year anniversary, and Xencor's release puts it in the third quarter of 2027.

Sources

More on Xencor

All Xencor (XNCR) coverage →